Tackling The Cancer Epidemic Using AI: A Hands On Session in Breast Cancer Detection

Terms of use

Terms of Use

The use of this site and the content contained therein is governed by the Terms of Use. When you use this site you acknowledge that you have read the Terms of Use and that you accept and will be bound by the terms hereof and such terms as may be modified from time to time.

All text, graphics, audio, design and other works on the site are the copyrighted works of nasscom unless otherwise indicated. All rights reserved.
Content on the site is for personal use only and may be downloaded provided the material is kept intact and there is no violation of the copyrights, trademarks, and other proprietary rights. Any alteration of the material or use of the material contained in the site for any other purpose is a violation of the copyright of nasscom and / or its affiliates or associates or of its third-party information providers. This material cannot be copied, reproduced, republished, uploaded, posted, transmitted or distributed in any way for non-personal use without obtaining the prior permission from nasscom.
The nasscom Members login is for the reference of only registered nasscom Member Companies.
nasscom reserves the right to modify the terms of use of any service without any liability. nasscom reserves the right to take all measures necessary to prevent access to any service or termination of service if the terms of use are not complied with or are contravened or there is any violation of copyright, trademark or other proprietary right.
From time to time nasscom may supplement these terms of use with additional terms pertaining to specific content (additional terms). Such additional terms are hereby incorporated by reference into these Terms of Use.

Disclaimer

The Company information provided on the nasscom web site is as per data collected by companies. nasscom is not liable on the authenticity of such data.
nasscom has exercised due diligence in checking the correctness and authenticity of the information contained in the site, but nasscom or any of its affiliates or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this site. The information from or through this site is provided "as is" and all warranties express or implied of any kind, regarding any matter pertaining to any service or channel, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement are disclaimed. nasscom and its affiliates and associates shall not be liable, at any time, for any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communications line failure, theft or destruction or unauthorised access to, alteration of, or use of information contained on the site. No representations, warranties or guarantees whatsoever are made as to the accuracy, adequacy, reliability, completeness, suitability or applicability of the information to a particular situation.
nasscom or its affiliates or associates or its employees do not provide any judgments or warranty in respect of the authenticity or correctness of the content of other services or sites to which links are provided. A link to another service or site is not an endorsement of any products or services on such site or the site.
The content provided is for information purposes alone and does not substitute for specific advice whether investment, legal, taxation or otherwise. nasscom disclaims all liability for damages caused by use of content on the site.
All responsibility and liability for any damages caused by downloading of any data is disclaimed.
nasscom reserves the right to modify, suspend / cancel, or discontinue any or all sections, or service at any time without notice.

For any grievances under the Information Technology Act 2000, please get in touch with Grievance Officer, Mr. Anirban Mandal at data-query@nasscom.in.

New

See all

No notification found.

Tackling The Cancer Epidemic Using AI: A Hands On Session in Breast Cancer Detection

Sindhuja Balaji

@sindhuja.balaji

September 30, 2019

2148

In recent times, breast cancer has become the most common type of cancer affecting women worldwide accounting for 25% of all cancer cases and affected 3.5 million people in 2017-18. Early diagnosis in these cases significantly increases the chances of survival. The key challenge in cancer detection is how to classify tumours into malignant or benign. Research indicates that most experienced physicians can diagnose cancer with 79% accuracy while using artificial intelligence based diagnosis, it is possible to achieve 91% accuracy.

Ahead of Breast Cancer Awareness Month (October), NASSCOM CoE IoT-AI Gurugram & Equonix Tech Lab organised a hands-on session on 28th September 2019, 10am onwards at the CoE Gurugram center on Breast Cancer detection. This was a paid session and there were over 50 attendees, consisting of basic & advanced developers from enterprises like Sopra Steria, United Health Group, TCS, HCL, Inventum Technologies, Publicis Sapient, Globallogic and startups like Attentive AI, Empass, Anasakta Labs, NEbulARC, SirionLabs & Vision Networkz. Students from ICGEB/JMI, Indira Gandhi Delhi Technical University etc also participated in the session.

Live Coding Workshop on Breast Cancer Detection

The session first half focussed on Wisconsin Diagnostic Cancer (WDBC) & Invasive Ductal Carcinoma (IDC) datasets insights, Visualization of Dataset, feature selection and why they are chosen and how the physical parameters are translated into a dataset. In the second part, the focus was on Feature Selection and CNN, random forest based classification of cancer as malignant or benign followed by the optimised the deployment strategy & cost estimation

WISCONSIN DIAGNOSTIC BREAST CANCER (WDBC):

The samples consist of visually assessed nuclear features of Fine Needle Aspirates (FNAs) taken from patients. Attributes 3 to 11 were used to form a 9-dimensional vector which was used to obtain a neural network to discriminate between benign and malignant samples. Cross-validation was used to project the accuracy of the diagnostic algorithm.

Field	Attribute
1	Sample code number
2	Class: 2 for benign, 4 for malignant
3	Clump Thickness
4	Uniformity of Cell Size
5	Uniformity of Cell Shape
6	Marginal Adhesion
7	Single Epithelial Cell Size
8	Bare Nuclei
9	Bland Chromatin
10	Normal Nucleoli
11	Mitoses

INVASIVE DUCTAL CARCINOMA (IDC)

Invasive Ductal Carcinoma dataset originally consisted of 162 slide images, scanned at 40x. From that, 277,524 patches of 50×50 pixels (which is converted to 32 x 32pixels to fit the model architecture) were extracted, including, 198,738 IDC negative examples & 78,786 IDC positive examples. Each image in the dataset is labelled based on the following parameters:

Patient ID: 10253_idx5
x-coordinate of the crop: 1,351
y-coordinate of the crop: 1,101
Class label: 0 (0 indicates no IDC while 1 indicates IDC)

CNN Architecture used:

Used exclusively 3×3 CONV filters, similar to VGGNet
Stacked multiple 3×3 CONV filters on top of each other prior to performing max-pooling (again, similar to VGGNet
But unlike VGGNet, used depth-wise separable convolution rather than standard convolution layer
Keras Sequential API is used to build CancerNet

The model achieved 86% classification accuracy, 85% sensitivity, and 85% specificity.

CODE REPOSITORY:

https://bitbucket.org/tdequonix/cancer_detect_meetup_resources/src/master/

Enter git clone and the repository URL at your command line:

git clone https://shantanugaur@bitbucket.org/tdequonix/cancer_detect_meetup_resources.git

build_dataset.py : Builds the dataset by splitting images into training, validation and testing sets.
cancernet.py : Contains CancerNet breast cancer classification CNN
train_model.py : Responsible for training and evaluation of Keras classification model

DATASET & PRESENTATION:

https://drive.google.com/open?id=1kgbtXSkDhDXK1aTCb8l1GvQcOn3iTjZQ

NEXT SESSION:

The next session will be focused on the Prognostic System. This recently put into clinical practice, is a method that predicts when the cancer is likely to recur in patients that have had their cancers excised. This gives the physician and the patient better information with which to plan treatment and may eliminate the need for a prognostic surgical procedure. The novel feature of the predictive approach is the ability to handle cases for which cancer has not recurred as well as cases for which cancer has recurred at a specific time.

For further details, contact Shantanu Gaur (shantanu@nasscom.in)

For more updates, follow NASSCOM CoE IoT-DSAI on LinkedIn, Twitter, Facebook, and Youtube

breast cancer breast cancer screening AI for breast cancer detection NASSCOM CoE IoT AI Gurugram cancer detection using technology Wisconsin Diagnostic Breast Cancer Invasive Ductal Carcinoma

Disclaimer

That the contents of third-party articles/blogs published here on the website, and the interpretation of all information in the article/blogs such as data, maps, numbers, opinions etc. displayed in the article/blogs and views or the opinions expressed within the content are solely of the author's; and do not reflect the opinions and beliefs of NASSCOM or its affiliates in any manner. NASSCOM does not take any liability w.r.t. content in any manner and will not be liable in any manner whatsoever for any kind of liability arising out of any act, error or omission. The contents of third-party article/blogs published, are provided solely as convenience; and the presence of these articles/blogs should not, under any circumstances, be considered as an endorsement of the contents by NASSCOM in any manner; and if you chose to access these articles/blogs , you do so at your own risk.